The economic burden of community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA).

TitleThe economic burden of community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA).
Publication TypeJournal Article
Year of Publication2013
AuthorsLee BY, Singh A, David MZ, Bartsch SM, Slayton RB, Huang SS, Zimmer SM, Potter MA, Macal CM, Lauderdale DS, Miller LG, Daum RS
JournalClin Microbiol Infect
Volume19
Issue6
Pagination528-36
Date Published2013 Jun
ISSN1469-0691
KeywordsAdolescent, Adult, Aged, Aged, 80 and over, Child, Child, Preschool, Community-Acquired Infections, Computer Simulation, Cost of Illness, Humans, Infant, Infant, Newborn, Methicillin-Resistant Staphylococcus aureus, Middle Aged, Models, Economic, Staphylococcal Infections, United States, Young Adult
Abstract

The economic impact of community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) remains unclear. We developed an economic simulation model to quantify the costs associated with CA-MRSA infection from the societal and third-party payer perspectives. A single CA-MRSA case costs third-party payers $2277-$3200 and society $7070-$20 489, depending on patient age. In the United States (US), CA-MRSA imposes an annual burden of $478 million to 2.2 billion on third-party payers and $1.4-13.8 billion on society, depending on the CA-MRSA definitions and incidences. The US jail system and Army may be experiencing annual total costs of $7-11 million ($6-10 million direct medical costs) and $15-36 million ($14-32 million direct costs), respectively. Hospitalization rates and mortality are important cost drivers. CA-MRSA confers a substantial economic burden on third-party payers and society, with CA-MRSA-attributable productivity losses being major contributors to the total societal economic burden. Although decreasing transmission and infection incidence would decrease costs, even if transmission were to continue at present levels, early identification and appropriate treatment of CA-MRSA infections before they progress could save considerable costs.

DOI10.1111/j.1469-0691.2012.03914.x
Alternate JournalClin. Microbiol. Infect.
PubMed ID22712729
PubMed Central IDPMC3463640
Grant List1RC4AI092327-01 / AI / NIAID NIH HHS / United States
5U01GM087729-03 / GM / NIGMS NIH HHS / United States
5U54GM088491-02 / GM / NIGMS NIH HHS / United States
K23 AI095361 / AI / NIAID NIH HHS / United States
RC4 AI092327 / AI / NIAID NIH HHS / United States
U01 GM087729 / GM / NIGMS NIH HHS / United States
U54 GM088491 / GM / NIGMS NIH HHS / United States
UL1 TR000124 / TR / NCATS NIH HHS / United States
Publication Categories: